Q901

CDK7 inhibitor · Qurient Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Q901, covering 2025-08-17 to 2025-08-17. Get the full timeline:

Most recent: Clinical Trial Update: Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors [Phase 1, Phase 2]